Category Archives: Genetics

Podcast: The future of cancer careHow genomics is transforming research and treatment for all – Genetic Literacy Project

Geneticist Dr Kat Arney takes a look at how genomic technologies are transforming cancer careand the importance of making sure these advances are available to all, on the latest episode of the Genetics Societys Genetics Unzipped podcast, sponsored by Thermo Fisher Scientific.

Arney looks at the progress weve made and what the future looks like for cancers that afflict both adults and children, as well as exploring how important fast genetic testing is to patients and how new technology could help make genetic data more accessible. Joining her on this episode of the show:

Full show notes, transcript, music credits and references online at GeneticsUnzipped.com.

Genetics Unzipped is the podcast from the UK Genetics Society, presented by award-winning science communicator and biologist Kat Arney and produced by First Create the Media. Follow Kat on Twitter @Kat_Arney, Genetics Unzipped @geneticsunzip, and the Genetics Society at @GenSocUK

Subscribe from Apple podcasts, Spotify, or wherever you get your podcasts.

Original post:
Podcast: The future of cancer careHow genomics is transforming research and treatment for all - Genetic Literacy Project

Animal Genetic Products Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and Forecast…

The market research report on the Global Animal Genetic Products Market is a conclusive study of the various techniques and advancements in the Animal Genetic Products sector. The report analyzes numerous segments of the market from industrial chain analysis to cost structure analysis. It puts a special emphasis on the production and end-user segment of the Animal Genetic Products market. The Animal Genetic Products market is anticipated to grow at a CAGR of XX% during the forecast period of 2020-2027 to reach a market value of USD XX billion.

The impact of the COVID-19 crisis on the industry and individual segment is studied in the report. It offers a comprehensive analysis of the current and future market trends with regard to the pandemics effect on the industry. The report is updated with the latest economic scenario and dynamic changes in the market trends owing to the pandemic.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1344

The varying landscape for the overall Animal Genetic Products industry is offered in the report providing a comprehensive pattern of the Animal Genetic Products industry and its rapidly changing market landscape. The details mentioned in the report can assist the players in formulating strategies and approaches to gain a robust footing in the industry. Profitable insights and analytical data have been covered in the report to offer insight into global expansion strategies. Each key manufacturer and producer have been thoroughly assessed in the report.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Genus Plc, Hendrix Genetics BV, Alta Genetics, CRV Holdings B.V., Neogen Corporation, VatGen, Animal Genetics Inc., Zoetis, Urus, and Envigo.

The market report sheds light on the latest strategic developments and growth patterns of the market players to provide a clear view. The report is an investigative study that provides insights for the players to formulate their business expansion strategies and expand their footing in the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1344

Factors affecting the leading industry players and the recent technological developments are covered in the report. The report provides detailed statistical data to help the leading companies to gain a deeper understanding of the workings of the industry. Every leading organization and players partaking in industrial development are studied in the report and a comprehensive overview of the competitive landscape is offered in the report.

Live Animals Outlook (Revenue, USD Billion; 2018-2026)

Genetic Material Outlook (Revenue, USD Billion; 2018-2026)

Testing Services Outlook (Revenue, USD Billion; 2018-2026)

Request customization of the report @ https://www.reportsanddata.com/make-enquiry-form/1344

The report offers:

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/animal-genetic-products-market

Thank you for reading our report. For further queries, kindly get in touch with us and our team will provide excellent assistance in customization of the report according to your requirements.

Go here to see the original:
Animal Genetic Products Market Emerging Trends, Business Opportunities, Segmentation, Production Values, Supply-Demand, Brand Shares and Forecast...

Genetic Study Uncovers Mutation Associated with Fibromuscular Dysplasia – University of Michigan Health System News

Understanding of fibromuscular dysplasia (FMD), a rare blood vessel disease, is making the jump from the laboratory to the clinic with new findings about a genetic variant.

Researchers found the mutation in a gene that is associated with classical Ehlers-Danlos Syndrome as well, in multifocal FMD. That means it could help clinicians understand whether a person inherited the disease from a relative or another mechanism, in affected families.

We identified four independent families with the same genetic variant in COL5A1 and vascular disease in a pattern of dysplasia-associated arterial disease, including arterial dissections and multifocal FMD, says senior author Santhi Ganesh, M.D., an associate professor of internal medicine and human genetics, and a cardiologist at the Michigan Medicine Frankel Cardiovascular Center. Notably, the variant appears to have been inherited from a shared ancestral founder.

Ganesh says the implication of this finding is that other carriers of this variant may exist in the population. The pattern of arterial involvement among carriers of the COL5A1 G514S variant is unique, providing clinicians with clues for when to suspect its involvement.

The identified genetic variant meets clinical criteria for pathogenicity a first for FMD, she says.

Further, additional variants in the COL5A1 gene were associated with a higher rate of arterial dissections among individuals with multifocal FMD.

Paper cited: A Novel Recurrent COL5A1 Genetic Variant Is Associated With a Dysplasia-Associated Arterial Disease Exhibiting Dissections and Fibromuscular Dysplasia. Arteriosclerosis, Thrombosis, and Vascular Biology. DOI: 10.1161/ATVBAHA.119.313885

Read more from the original source:
Genetic Study Uncovers Mutation Associated with Fibromuscular Dysplasia - University of Michigan Health System News

A Remarkable Run: Rothschild Reflects on 50 Years of Genetics – Pork Magazine

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Firefox Add-ons Store.

Originally posted here:
A Remarkable Run: Rothschild Reflects on 50 Years of Genetics - Pork Magazine

Unsuspecting Wadsworth woman finds close relatives through genetic testing – News 5 Cleveland

WADSWORTH, Ohio High-tech genetic ancestry tests retail for a couple hundred dollars.

You get to find out all this information about genetics and all of that, Tiffany Leonard said.

But the gift Leonard received after shipping off a quick swab of her saliva was priceless.

So I didn't know a lot about any genetics or medical issues that ran in our family, Leonard said. So that's really the focus of it, was to find out that stuff. I got a lot more than I bargained for.

Growing up, Leonard said she had questions about where she came from, but she was raised by a loving father and kept that skepticism tucked away for years.

I looked at the results and that was the end of it. I never looked at it again, Leonard said. My dad used to say he wasn't really sure if I was his or not because I had white hair and everybody else had brown hair.

However, she said her 23andMe results were impossible to ignore.

You'll have lots of relatives that you are like barely connected with, Leonard said. It says first cousins and second cousins. And I was like, That's weird because my dad was an only child.

Through some digging and connecting with relatives she discovered through the ancestry program, she learned the man who raised her was not her biological father.

So, of course, my whole world is reeling, Leonard said.

For more than a decade, her biological father was living just miles away.

He called me and said, Im your dad. And I was mind blown, Leonard said. And Ive worked at the hospital for 13 years and Ive passed his house for the last 13 years.

As a successful woman with three children of her own, Leonard said the last year has given her a mirror and a history she never knew existed.

I can see where my personal qualities come from, like walking into the screen door, and that part's been really fun, Leonard said. You kind of just stare at each other like, Holy mackerel. That's my dad.

Read more here:
Unsuspecting Wadsworth woman finds close relatives through genetic testing - News 5 Cleveland

‘It’s all in the brain’: The science behind stuttering – Genetic Literacy Project

Gerald Maguire has stuttered since childhood, but you might not guess it from talking to him. For the past 25 years, Maguire a psychiatrist at the University of California, Riverside has been treating his disorder with antipsychotic medications not officially approved for the condition. Only with careful attention might you discern his occasional stumble on multisyllabic words like statistically and pharmaceutical.

Maguire has plenty of company: More than 70 million people worldwide, including about 3 million Americans, stutter that is, they have difficulty with the starting and timing of speech, resulting in halting and repetition. That number includes approximately 5 percent of children, many of whom outgrow the condition, and 1 percent of adults. Their numbers includepresidential candidate Joe Biden,deep-voiced actor James Earl Jonesand actressEmily Blunt. Though those people and many others, including Maguire, have achieved career success, stuttering can contribute to social anxiety and draw ridicule or discrimination by others.

Maguire has been treating people who stutter, and researching potential treatments, for decades. He receives daily emails from people who want to try medications, join his trials, or even donate their brains to his university when they die. Hes now embarking on a clinical trial of a new medication, called ecopipam, that streamlined speech and improved quality of life in a small pilot study in 2019.

Others, meanwhile, are delving into the root causes of stuttering, which also may point to novel treatments. In past decades, therapists mistakenly attributed stuttering to defects of the tongue and voice box, to anxiety, trauma or even poor parenting and some still do. Yet others have long suspected that neurological problems might underlie stuttering, says J. Scott Yaruss, a speech-language pathologist at Michigan State University in East Lansing. The first data to back up that hunch came in 1991, Yaruss says, when researchers reportedaltered blood flow in the brains of people who stuttered. Over the past two decades, continuing research has made it more apparent that stuttering is all in the brain.

We are in the middle of an absolute explosion of knowledge being developed about stuttering, Yaruss says.

Theres still a lot to figure out, though. Neuroscientists have observed subtle differences in the brains of people who stutter, but they cant be certain if those differences are the cause or a result of the stutter. Geneticists are identifying variations in certain genes that predispose a person to stutter, but the genes themselves are puzzling: Only recently have their links to brain anatomy become apparent.

Maguire, meanwhile, is pursuing treatments based on dopamine, a chemical messenger in the brain that helps to regulate emotions and movement (precise muscle movements, of course, are needed for intelligible speech). Scientists are just beginning to braid these disparate threads together, even as they forge ahead with early testing for treatments based on their discoveries.

Looking at a standard brain scan of someone who stutters, a radiologist wont notice anything amiss. Its only when experts look closely, with specialized technology that shows the brains in-depth structure and activity during speech, that subtle differences between groups who do and dont stutter become apparent.

The problem isnt confined to one part of the brain. Rather, its all about connections between different parts, says speech-language pathologist and neuroscientist Soo-Eun Chang of the University of Michigan in Ann Arbor. For example, in the brains left hemisphere, people who stutter often appear to have slightly weaker connections between the areas responsible for hearing and for the movements that generate speech. Chang has also observed structural differences in the corpus callosum, the big bundle of nerve fibers that links the left and right hemispheres of the brain.

These findings hint that stuttering might result from slight delays in communication between parts of the brain. Speech, Chang suggests, would be particularly susceptible to such delays because it must be coordinated at lightning speed.

Chang has been trying to understand why about 80 percent of kids who stutter grow up to have normal speech patterns, while the other 20 percent continue to stutter into adulthood. Stuttering typically begins when children first start stringing words together into simple sentences, around age 2. Chang studies children for up to four years, starting as early as possible, looking for changing patterns in brain scans.

Its no easy feat to convince such young children to hold still in a giant, thumping, brain-imaging machine. The team has embellished the scanner with decorations that hide all the scary parts. (It looks like an ocean adventure, Chang says.) In kids who lose their stutter, Changs team has observed that the connections between areas involved in hearing and ones involved in speech movements get stronger over time. Butthat doesnt happen in children who continue to stutter.

In another study, Changs group looked at how the different parts of the brain work simultaneously, or dont, using blood flow as a proxy for activity. They found a link between stuttering and a brain circuit called the default mode network, which has roles in ruminating over ones past or future activities, as well as daydreaming. In children who stutter, the default mode network seems to insert itself like a third person butting in on a romantic date intothe conversation between networks responsible for focusing attention and creating movements. That could also slow speech production, she says.

These changes to brain development or structure might be rooted in a persons genes, but an understanding of this part of the problem has also taken time to mature.

In early 2001, geneticist Dennis Drayna received a surprising email: I am from Cameroon, West Africa. My father was a chief. He had three wives and I have 21 full and half siblings. Almost all of us stutter, Drayna recalls it saying. Do you suppose there could be something genetic in my family?

Drayna, who worked at the National Institute on Deafness and Other Communication Disorders, already had a longstanding interest in the inheritance of stuttering. His uncle and elder brother stuttered, and his twin sons did so as children. But he was reluctant to make a transatlantic journey based on an email, and wary that his clinical skills werent up to analyzing the familys symptoms. He mentioned the email to current National Institutes of Health director Francis Collins (director of the National Human Genome Research Institute at that time), who encouraged him to check it out, so he booked a ticket to Africa. He has also traveled to Pakistan, where intermarriage of cousins can reveal gene variants linked to genetic disorders in their children.

Even with those families, finding the genes was slow going: Stuttering isnt inherited in simple patterns like blood types or freckles are. But eventually, Draynas team identified mutations in four genes GNPTAB,GNPTGandNAGPAfrom the Pakistan studies, andAP4E1from the clan in Cameroonthat he estimates may underlie as many as one in five cases of stuttering.

Oddly, none of the genes that Drayna identified have an obvious connection to speech. Rather, they all are involved in sending cellular materials to the waste-recycling compartment called thelysosome. It took more work before Draynas team linked the genes to brain activity.

They started by engineering mice to have one of the mutations theyd observed in people, in the mouse version ofGNPTAB, to see if it affected the mices vocalizations.Mice can be quite chatty, but much of their conversation takes place in an ultrasonic range that people cant hear. Recording the ultrasonic calls of pups, the team observed patterns similar to human stuttering. They have all these gaps and pauses in their train of vocalizations, says Drayna, who cowrote an overview ofgenetics research on speech and language disordersfor theAnnual Review of Genomics and Human Genetics.

Still, the team struggled to spot any clear defect in the animals brains until one determined researcher found that there were fewer of the cells called astrocytes in the corpus callosum. Astrocytesdo big jobs that are essential for nerve activity: providing the nerves with fuel, for example, and collecting wastes. Perhaps, Drayna muses, the limited astrocyte population slows down communication between the brain hemispheres by a tiny bit, only noticeable in speech.

Draynas research has received mixed reviews. Its really been the pioneering work in the field, says Angela Morgan, a speech-language pathologist at the University of Melbourne and Murdoch Childrens Research Institute in Australia. On the other hand, Maguire has long doubted that mutations in such important genes, used in nearly all cells, could cause defects only in the corpus callosum, and only in speech. He also finds it difficult to compare mouse squeaks to human speech. Thats a bit of a stretch, he says.

Scientists are sure there are more stuttering genes to find. Drayna has retired, but Morgan and collaborators areinitiating a large-scale studyin the hopes of identifying additional genetic contributors in more than 10,000 people.

Maguire has been tackling stuttering from a very different angle: investigating the role of dopamine, a key signaling molecule in the brain. Dopamine can ramp up or down the activity of neurons, depending on the brain location and the nerve receptors it sticks to. There are five different dopamine receptors (named D1, D2, and so on) that pick up the signal and respond.

During the 1990s, Maguire and colleagues were among the first to use a certain kind of brain scan, positron emission tomography, on people who stutter. They foundtoomuch dopamine activityin these peoples brains. That extra dopamine seems to stifle the activity of some of the brain regions that Chang and others have linked to stuttering.

Backing up the dopamine connection, other researchers reported in 2009 that people with a certainversion of the D2 receptor gene, one that indirectly enhances dopamine activity, are more likely to stutter.

So Maguire wondered: Could blocking dopamine be the answer? Conveniently, antipsychotic drugs do just that. Over the years, Maguire has conducted small, successful clinical studies with these medications includingrisperidone,olanzapineandlurasidone. (Personally, he prefers the last because it doesnt cause as much weight gain as the others.) The result: Your stuttering wont completely go away, but we can treat it, he says.

None of those medications are approved for stuttering by the US Food and Drug Administration, and they can cause unpleasant side effects, not just weight gain but also muscle stiffness and impaired movement. In part, thats because they act on the D2 version of the dopamine receptor. Maguires new medication, ecopipam, works on the D1 version, which he expects will diminish some side effects though hell have to watch for others, such as weight loss and depression.

In a small study of 10 volunteers, Maguire, Yaruss and colleagues found that people who took ecopipamstuttered lessthan they did pre-treatment. Quality-of-life scores, related to feelings such as helplessness or acceptance of their stutter, also improved for some participants.

Ecopipam isnt the only treatment under consideration. Back in Michigan, Chang hopes thatstimulation of specific parts of the brain during speech could improve fluency. The team uses electrodes on the scalp to gently stimulate a segment of the hearing area, aiming to strengthen connections between that spot and the one that manages speech movements. (This causes a brief tickle sensation before fading, Chang says.) The researchers stimulate the brain while the person undergoes traditional speech therapy, hoping to enhance the therapys effects. Because of the Covid-19 pandemic, the team had to stop the study with 24 subjects out of a planned 50. Theyre analyzing the data now.

Dopamine, cellular waste disposal, neural connectivity how do they fit together? Chang notes that one of the brains circuits involved in stuttering includes two areas that make and use dopamine, which might help explain why dopamine is important in the disorder.

She hopes that neuroimaging can unite the different ideas. As a first stab, she and collaborators compared the problem areas identified by her brain scans tomaps of where various genes are active in the brain. Two of Draynas genes,GNPTGandNAGPA, were active at high levels in the speech and hearing network in the brains of non-stutterers, she saw. That suggests those genes are really needed in those areas, bolstering Draynas hypothesis that defects in the genes would interfere with speech.

The team also observed something novel: Genes involved in energy processing were active in the speech and hearing areas. Theres a big rise in brain activity during the preschool years, when stuttering tends to start, Chang says. Perhaps, she theorizes, those speech-processing regions dont get all the energy they need at a time when they really need to be cranking at maximum power. With that in mind, she plans to look for mutations in those energy-control genes in children who stutter. There are obviously a lot of dots that need to be connected, she says.

Maguire is also connecting dots: He says hes working on a theory to unite his work with Draynas genetic findings. Meanwhile, after struggling through med school interviews and choosing a career in talk therapy despite his difficulties with speech, hes hopeful about ecopipam: With colleagues, hes starting a new study that willcompare 34 people on ecopipam with 34 on placebo. If that treatment ever becomes part of the standard stuttering tool kit, he will have realized a lifelong dream.

Amber Dance is an award-winningfreelance science journalist based in Southern California. She contributes to publications includingPNAS Front Matter,The Scientist, andNature. Find Amber on Twitter @amberldance

A version of this article was originally published at Knowable Magazine and has been republished here with permission. Knowable can be found on Twitter @KnowableMag. Sign up for their newsletter here.

Read more here:
'It's all in the brain': The science behind stuttering - Genetic Literacy Project

Roche looks to genetic modifiers for new drug targets, teaming up with Dutch biotech in $375M deal – Endpoints News

Roche is gambling on a new way of discovering drug targets and, ultimately, promising to infuse more than $375 million into a small biotech if all goes well.

A spinout of the Netherlands Cancer Institute and Oxford University, Scenic Biotech set out to pioneer a field thats gaining some traction among top VCs in the US: to harness the natural protecting powers of genetic modifiers specific genes that suppress a disease phenotype.

After each getting a PhD from the prestigious Dutch research center and spending time in the Boston/Cambridge biotech hub, Thijn Brummelkamp and Sebastian Nijman built their functional genomics platform and named it Cell-Seq. The tech allows scientists to sift through all 20,000 genes in haploid cells (which have only one set of chromosomes), identify the genes that modify a given disease, and create a library of maps pinpointing them.

There have been other modifiers discovered but these have mostly been discovered by serendipity, Nijman, whos also the CSO, told Endpoints News. What we are now doing is doing this systematically.

Oscar Izeboud, a former banker who was recruited to be CEO this July, put it this way: Its a very fast way to find a needle in a haystack.

Once they find it, the strategy is to then find gene products proteins that can be targeted with small molecule drugs or antibodies. In most cases they would be enzymes, such as QPCTL, which Scenic believes is a druggable modifier of the CD47 checkpoint.

The other internal efforts have mainly focused on rare inherited metabolic disorders, where Nijman and Izeboud believe the 20-people-and-growing team can handle the clinical work.

Their new partners at Genentech are interested in an area that Scenic has not gone into. In addition to the undisclosed upfront, the deal covers target selection fees as well as milestones and royalties.

Scenic, though, isnt the only startup claiming to have the necessary tools to unpack genetic modifiers an idea thats central to the mystifying notion that people born into the same family, with the same genes, dont always have the same disease.

San Francisco-based Maze Therapeutics launched last year with $191 million from a syndicate led by ARCH and Third Rock, boasting a similar genetics platform designed to unearth new targets. Nessan Birminghams Triplet Therapeutics, meanwhile, is focused on the DNA level, leveraging antisense oligonucleotides to hit the DNA damage response pathway.

In comparison Scenics beginning was much more humble, raising 6.5 million from European firms BioGeneration Ventures and INKEF Capital, with some support from the university-affiliated Oxford Sciences Innovation and later the Dutch government.

But its not stopping Nijman from dreaming big.

Aside from the big Roche collaboration, he also has in his corner seasoned drug such as GSK vet Chas Bountra and cell therapy expert Ton Schumacher, whos just embarked on his own new venture with Arie Belldegrun and David Chang. If anything, the buzz that rivals are generating is welcome.

People are starting to realize and wake up to the fact that this is now possible, Nijman said. We can now go after this type of drug target.

Read more:
Roche looks to genetic modifiers for new drug targets, teaming up with Dutch biotech in $375M deal - Endpoints News

New Genetic System Can Halt or Eliminate Gene Drive in the Wild – Technology Networks

In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance. Based on CRISPR technology, such gene drives are poised to move from the laboratory into the wild where they are being engineered to suppress devastating diseases such as mosquito-borne malaria, dengue, Zika, chikungunya, yellow fever and West Nile. Gene drives carry the power to immunize mosquitoes against malarial parasites, or act as genetic insecticides that reduce mosquito populations.

Although the newest gene drives have been proven to spread efficiently as designed in laboratory settings, concerns have been raised regarding the safety of releasing such systems into wild populations. Questions have emerged about the predictability and controllability of gene drives and whether, once let loose, they can be recalled in the field if they spread beyond their intended application region.

Now, scientists at the University of California San Diego and their colleagues have developed two new active genetic systems that address such risks by halting or eliminating gene drives in the wild. On Sept.18, 2020 in the journal Molecular Cell, research led by Xiang-Ru Xu, Emily Bulger and Valentino Gantz in the Division of Biological Sciences offers two new solutions based on elements developed in the common fruit fly.

One way to mitigate the perceived risks of gene drives is to develop approaches to halt their spread or to delete them if necessary, said Distinguished Professor Ethan Bier, the papers senior author and science director for the Tata Institute for Genetics and Society. Theres been a lot of concern that there are so many unknowns associated with gene drives. Now we have saturated the possibilities, both at the genetic and molecular levels, and developed mitigating elements.

The first neutralizing system, called e-CHACR (erasing Constructs Hitchhiking on the Autocatalytic Chain Reaction) is designed to halt the spread of a gene drive by shooting it with its own gun. e-CHACRs use the CRISPR enzyme Cas9 carried on a gene drive to copy itself, while simultaneously mutating and inactivating the Cas9 gene. Xu says an e-CHACR can be placed anywhere in the genome.

Without a source of Cas9, it is inherited like any other normal gene, said Xu. However, once an e-CHACR confronts a gene drive, it inactivates the gene drive in its tracks and continues to spread across several generations chasing down the drive element until its function is lost from the population.

The second neutralizing system, called ERACR (Element Reversing the Autocatalytic Chain Reaction), is designed to eliminate the gene drive altogether. ERACRs are designed to be inserted at the site of the gene drive, where they use the Cas9 from the gene drive to attack either side of the Cas9, cutting it out. Once the gene drive is deleted, the ERACR copies itself and replaces the gene-drive.

If the ERACR is also given an edge by carrying a functional copy of a gene that is disrupted by the gene drive, then it races across the finish line, completely eliminating the gene drive with unflinching resolve, said Bier.

The researchers rigorously tested and analyzed e-CHACRs and ERACRs, as well as the resulting DNA sequences, in meticulous detail at the molecular level. Bier estimates that the research team, which includes mathematical modelers from UC Berkeley, spent an estimated combined 15 years of effort to comprehensively develop and analyze the new systems. Still, he cautions there are unforeseen scenarios that could emerge, and the neutralizing systems should not be used with a false sense of security for field-implemented gene drives.

Such braking elements should just be developed and kept in reserve in case they are needed since it is not known whether some of the rare exceptional interactions between these elements and the gene drives they are designed to corral might have unintended activities, he said.

According to Bulger, gene drives have enormous potential to alleviate suffering, but responsibly deploying them depends on having control mechanisms in place should unforeseen consequences arise. ERACRs and eCHACRs offer ways to stop the gene drive from spreading and, in the case of the ERACR, can potentially revert an engineered DNA sequence to a state much closer to the naturally-occurring sequence.

Because ERACRs and e-CHACRs do not possess their own source of Cas9, they will only spread as far as the gene drive itself and will not edit the wild type population, said Bulger. These technologies are not perfect, but we now have a much more comprehensive understanding of why and how unintended outcomes influence their function and we believe they have the potential to be powerful gene drive control mechanisms should the need arise.

Reference: Xu X-RS, Bulger EA, Gantz VM, et al. Active Genetic Neutralizing Elements for Halting or Deleting Gene Drives. Molecular Cell. 2020. doi:10.1016/j.molcel.2020.09.003.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
New Genetic System Can Halt or Eliminate Gene Drive in the Wild - Technology Networks

Indistinguishable from Nazi rhetoric: Trumps racehorse theory of genetics is profoundly racist its also why he thinks hes a natural-born genius -…

Over the past five years or so, Ive had no problem using the F word (fascism) to describe whats been happening under President Trump and the Republican Party.I wrote about it here in Salonall the way back in 2015, noting that I wasnt the only one. In fact, it was his fellow Republicans who were the first to use the term to describe him. All you have to do is go back and read that full-page newspaper ad Trumptook out in 1989, headlined Bring Back the Death Penalty, Bring Back Our Police, to understand his fundamental authoritarian nature.

Even though we knew from the beginning that we were dealing with an essentially authoritarianleader, our awareness of it has sometimes been subsumed amidthe sheer chaos of daily newsoverthe past five years. But if you look at the various issues Trump is most obsessed with, whether it was the lurid obsession with terrorist violence and refugees during the 2016 campaign or his preoccupation with immigrants, the pardoning of war criminals, his flirtations with dictators, the endless threats to jail his political opponents and muzzle the press, the valorizing of the Confederacy and the openly racist law and order campaign of this year,its pretty clear what gets himexcited along withhis devoted following.

But wait, you say:Donald Trump only cares about himself! Hes not interested in anything as abstract as issues, not even the ones that tickle his lizard brain. But these are not mutually exclusive things. You see, Donald Trump genuinely believes he is scientifically superior to all those others and that they must be kept in check, with whatever level of violence may benecessary.

He doesnt talk about this a whole lot, but it definitelycomesup from time to time. Just this past weekend in Minnesota, in the midst of one of his most rambling, racist rallies in a long while, Trump said this, startling quite a few people who perhaps werent aware of his deep andabiding belief in eugenics:

As a historian who has written about the Holocaust, Ill say bluntly: This is indistinguishable from the Nazi rhetoric that led to Jews, disabled people, LGBTQ, Romani and others being exterminated. This is America 2020. This is where the GOP has taken us. https://t.co/CHMLg804mp

Steve Silberman (@stevesilberman) September 20, 2020

The last time he brought this up was in May when he visited a Ford plantto praise the organization for some PPE initiative:

Hes a big believer in blood and soil. https://t.co/gYQUwJy56H

digby (@digby56) May 21, 2020

Trump is poorly educated, so he probably doesnt even knowthat such language evokes Nazi Germanys eugenics program and AdolfHitlers theory of the master race, especially when discussing the notorious anti-SemiteHenry Ford. But itsclear enough that regardless of the historical context, Trump is on Fords wavelength when it comes to eugenics.

Hes talked aboutbloodlines line before,weirdly tellinga group of British businessmen in 2018 thatyouve all got such good bloodlines in this room.Youve all got such amazing DNA.' He obviously didnt know anything about their bloodlines, but made the assumption they must be amazing because they were a bunch of rich, successfulwhite, men.

According to Trumpbiographer Michael DAntonio, hedoes believe in a racehorse theoryof human development. Its all about the breeding.

Im a big believer in natural ability, Trump told me during a discussion about his leadership traits, which he said came from a natural sense of how human relations work. If Obama had that psychology, Putin wouldnt be eating his lunch. He doesnt have that psychology and he never will because its not in his DNA. Later in this discussion, Trump said: I believe in being prepared and all that stuff. But in many respects, the most important thing is an innate ability.

Perhaps Trumps conviction that DNA not life experience is everything explains why he proudly claims that hes basically the same today as when he was a boy. When I look at myself in the first grade and I look at myself now, Im basically the same, he said. The temperament is not that different.

The racehorse theory of human development explains Trumps belief in his suitability for political leadership, despite the fact that he has never held office. Hes absolutely convinced that Americas problems will be solved by his God-given management skills, bankruptcies notwithstanding. You are either born with superior qualities the right DNA or you are not. And people get what they deserve. In his case, that includes the White House.

According to DAntonio, Donald Trump Jr. also told him that he believes in the racehorse theory as well, and that he too is in the high percentile on the bell curve, although his father scores even higher.

In Trumps case, the belief that he has great genes means that he is not required to study or consult experts or reallyever bother to learn anything. He explained this tothe Washington Post back in 2016:

He said in a series of interviews that he does not need to read extensively because he reaches the right decisions with very little knowledge other than the knowledge I [already] had, plus the words common sense, because I have a lot of common sense and I have a lot of business ability. He believes that when he makes decisions, people see that he instinctively knows the right thing to do: A lot of people said, Man, he was more accurate than guys who have studied it all the time.

This was most recently demonstrated in his bizarrecomments at the CDC last March:

!!! https://t.co/1V47k7dyB6

digby (@digby56) September 21, 2020

Youll note that he mentions once again that his uncle, JohnTrump an electrical engineer and inventor taught at MIT, which he believesconfers on him the same level of intelligence because of their shared genes.

For Trump, thisisnt just idle talk about an accomplished relative. It is central to his understanding of the world and his ability to navigate it. He simply does whatever he feels likein the moment, secure in the knowledge that it must be right because his instincts are superior to any book learning due to his great bloodlines:

Its easy to laugh at Trumps foolishness or assume that hes just blathering on as usual. But consider his obvious willingness to sacrifice the lives of hundreds of thousands of Americans to the deadly pandemic for his own purposes. As he has put it,Well let it wash over the countryandachieveherd mentality.Or what about the horrific conditions at the border over the past three years, most recently the accusations thatdoctors are performing hysterectomies and other sterilization procedureson immigrant women against their will. Think about what former Homeland Securitychief of staff Miles Taylorreported: This was the president of the United States who looked at me and told me, when were deciding who to let in to the U.S., he didnt want us to accept people who had quote, missing toes or funny foreheads. This is how the president talks about human beings.

Trumps absurd talk about his good German genes doesnt sound so funny when you consider his policies. Somewhere along the line, all these words of his and all the actions of his administration come together in a pattern in which his belief in eugenics fits right in with a program that looks an awful lot like that F word.

See original here:
Indistinguishable from Nazi rhetoric: Trumps racehorse theory of genetics is profoundly racist its also why he thinks hes a natural-born genius -...

Dementia run in the family? You can lower your risk by keeping a healthy heart – Study Finds

BOSTON A family history of dementia is by no means an absolute indictor of a future dementia diagnosis, according to a new study from Boston University. Researchers say that both family history and cardiovascular health influence an individuals chances of developing dementia.

So, people who are worried about dementia potentially being in their future due to genetics can mitigate their risk by focusing on cultivating a strong and robust cardiovascular system.

At the same time, however, these findings represent a bit of a double-edged sword. People who are both genetically inclined toward dementia and neglect their cardiovascular health are putting themselves in an especially precarious position regarding their cognitive future.

The study gives weight to the notion that while much of ones traits and proclivities can be traced to genetics, were all still very much in charge of their own future. Nothing is predetermined.

Regarding the studys findings, the presence of dementia-associated common gene variants alone were found to potentially double a persons risk of dementia. However, if that same person is in strong cardiovascular shape that dementia risk is cut in half.

Researchers say the effects of both genes and cardiovascular health on dementia risk are additive. This means either of those factors can solely raise or lower a persons dementia risk.

Just because you have a high genetic risk of dementia doesnt mean that you cant lower your risk by adopting a healthier lifestyle, says study lead author Dr. Gina Peloso, assistant professor of biostatistics at BUSPH, in a release.

Data on 1,211 people was used for this study. That information was originally collected as part of the Framingham Heart Study.That study single longest-running cardiovascular disease study performed in the United States. The project started in 1948, and the 1,211 people included in this study are the children of the original Farmingham study participants. Genetic data, cardiovascular health information collected between 1991-1995, and dementia screening results from sessions held starting in 1998 are all included in the analysis.

Ultimately, the studys authors found that people with a high dementia genetic risk score were 2.6 times more likely to develop dementia. Researchers zeroed in on a genotype, APOE 4, specifically linked to the condition. The genotype is found in 10-15% of the general population.

To gauge each persons cardiovascular health, the American Heart Associations seven components of cardiovascular health was used. Those components include: physical activity, cholesterol, healthy diet, blood pressure, smoking status, blood glucose, and weight.

The results are quite clear. The study shows that adults with strong cardiovascular health were 55% less likely to develop dementia.

We have long maintained that genetics is not destiny, that the impact of your family history and genetic risk can be lowered by healthy lifestyle choices. This is true for persons with low genetic risk and also for persons with high genetic risk of dementia, so it is never too soon and never too late to adopt a heart-healthy lifestyle, concludes senior study author Dr. Sudha Seshadri, founding director of the Glenn Biggs Institute for Alzheimers and Neurodegenerative Diseases at The University of Texas Health Science Center at San Antonio.

The study is published in Neurology.

See more here:
Dementia run in the family? You can lower your risk by keeping a healthy heart - Study Finds